The short version of DMSO stock fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Joy Osmanski as Paula Brooks / Tigress (season 3; recurring season 1; guest season 2):A member of the ISA who hunts the world's most dangerous humans. She is a gym teacher at Blue Valley High, the wife of "Crusher" Crock, and mother of Artemis Crock. In the second season, she breaks out of prison twice. In the third and final season, she moves in next door to the Whitmore-Dugans. Joel McHale as Sylvester Pemberton / Starman and Gerard Shugel / Ultra-Humanite (season 3; guest season 1; recurring season 2):A member of the original JSA who used an anti gravity Cosmic Staff invented by scientist Ted Knight that Courtney later finds. In the present, Ultra-Humanite forms an alliance with Icicle and Dragon King before transplanting his brain into Sylvester Pemberton's body in order to manipulate Stargirl and her JSA, and Dragon King's brain into Ultra-Humanite's albino gorilla body for him to "defeat" as Starman alongside Jordan's son before intending to run for president as a mouthpiece for Icicle to spread his ideals.
=== Equestrian sports === Capsaicin is a banned substance in equestrian sports because of its hypersensitizing and pain-relieving properties. At the show jumping events of the 2008 Summer Olympics, four horses tested positive for capsaicin, which resulted in disqualification.
=== Breast milk === It has been established that trans fats in human breast milk fluctuate with maternal consumption of trans fat, and that the amount of trans fats in the bloodstream of breastfed infants fluctuates with the amounts found in their milk. In 1999, reported percentages of trans fats (compared to total fats) in human milk ranged from 1% in Spain, 2% in France, 4% in Germany, and 7% in Canada and the U.S.
Sources: en.wikipedia.org
On 1 July, a WHO official said a ban on public gatherings remained, and people were required to wear masks in public. KCNA and Rodong Sinmun released images from a meeting on 2 July with Kim Jong Un and dozens of officials, none of whom were shown wearing masks. According to Dr. Edwin Salvador, the WHO's representative in North Korea, 922 people in the country were tested for COVID-19 and all had tested negative. On 25 July, Kim Jong Un attended an emergency meeting after a suspected COVID-19 case was reported in the city of Kaesong. Kim declared a state of emergency and imposed a lockdown on the city. The suspected case was reported to be an individual who had defected to South Korea three years earlier, before swimming back to North Korea in July (a rare case of "re-defection"). According to a South Korean senior health official, the individual was neither registered as a COVID-19 patient, nor classified as someone who came in contact with other patients. Two close contacts of the defector in South Korea tested negative for the virus. On 5 August, Salvador said the returning defector was tested but the "results were inconclusive". On 14 August, the three week lockdown in Kaesong and nearby areas was lifted by Kim Jong Un, after "the scientific verification and guarantee by a professional anti-epidemic organisation". According to South Korean intelligence, in August a North Korean official was executed for violating COVID-19 restrictions by bringing goods to Sinuiju from across the Chinese border.
=== Global expansion === The company elected to expand globally, and acquired other entities. In March 2002, Dr. Reddy's acquired BMS Laboratories, Beverley, and its wholly owned subsidiary Meridian Healthcare, for €14.81 million. These companies deal in oral solids, liquids and packaging, with manufacturing facilities in London and Beverley in the UK. Recently, Dr. Reddy's entered into an R&D and commercialisation agreement with Argenta Discovery Ltd., a private drug development company based in the UK, for the treatment of chronic obstructive pulmonary disease (COPD). Dr. Reddy's entered into a 10-year agreement with Rheoscience A/S of Denmark for the joint development and commercialisation of Balaglitazone (DRF-2593), a molecule for the treatment of type-2 diabetes. Rheoscience holds this product's marketing rights for the European Union and China, while the rights for the US and the rest of the world will be held by Dr. Reddy's. Dr. Reddy's conducted clinical trials of its cardiovascular drug RUS 3108 in Belfast, Northern Ireland, in 2005. The trials were conducted to study the safety and the pharmacokinetic profiles of the drug, which is intended for the treatment of atherosclerosis, a major cause of cardiovascular disorders. Dr. Reddy's entered into a marketing agreement with Eurodrug Laboratories, a pharmaceutical company based in Netherlands, for improving its product portfolio for respiratory diseases. It introduced a second-generation xanthine bronchodilator, doxofylline, which is used for the treatment of asthma and COPD patients.
The emu has a prominent place in Australian Aboriginal mythology, including a creation myth of the Yuwaalaraay and other groups in New South Wales who say that the sun was made by throwing an emu's egg into the sky; the bird features in numerous aetiological stories told across a number of Aboriginal groups. One story from Western Australia holds that a man once annoyed a small bird, who responded by throwing a boomerang, severing the arms of the man and transforming him into a flightless emu. The Kurdaitcha man of Central Australia is said to wear sandals made of emu feathers to mask his footprints. Many Aboriginal language groups throughout Australia have a tradition that the dark dust lanes in the Milky Way represent a giant emu in the sky. Several of the Sydney rock engravings depict emus, and the birds are mimicked in Indigenous dances. Hunting emus, known as kari in the Kaurna language, features in the major Dreaming story of the Kaurna people of the Adelaide region about the ancestor hero Tjilbruke. The emu is popularly but unofficially considered as a faunal emblem – the national bird of Australia. It appears as a shield bearer on the Coat of arms of Australia with the red kangaroo, and as a part of the Arms also appears on the Australian 50-cent coin. It has featured on numerous Australian postage stamps, including a pre-federation New South Wales 100th Anniversary issue from 1888, which featured a 2 pence blue emu stamp, a 36-cent stamp released in 1986, and a $1.35 stamp released in 1994.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.